Fig. 5: PGS stratifies the risk of death and adverse outcomes in individuals with HCM. | Nature Genetics

Fig. 5: PGS stratifies the risk of death and adverse outcomes in individuals with HCM.

From: Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings

Fig. 5: PGS stratifies the risk of death and adverse outcomes in individuals with HCM.

a–c, Cumulative all-cause mortality and adverse HCM outcomes after HCM diagnosis in 382 HCM cases from the UKB (a,b) and cumulative all-cause mortality in 683 HCM cases from GeL (c), stratified by PGS in the highest and lowest quintiles. Adverse HCM outcomes include death, stroke, cardiac arrest, implantable cardioverter-defibrillator implantation, septal reduction therapy (alcohol–septal ablation or surgical myectomy), LVAD implantation or cardiac transplantation. HR calculated using Cox proportional hazards model, adjusted for age, age2, sex and first ten genetic PCs, with two-sided P value.

Back to article page